MB 07811

Drug Profile

MB 07811

Alternative Names: MB07344; MB07811

Latest Information Update: 11 Apr 2011

Price : $50

At a glance

  • Originator Metabasis Therapeutics
  • Developer Ligand Pharmaceuticals
  • Class Antihyperlipidaemics; Obesity therapies; Organophosphorus compounds; Small molecules
  • Mechanism of Action Thyroid hormone receptor beta agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperlipidaemia

Most Recent Events

  • 11 Apr 2011 Discontinued - Phase-I for Hyperlipidaemia in USA (PO)
  • 29 Jan 2010 Metabasis Therapeutics has been acquired by Ligand Pharmaceuticals
  • 10 Mar 2009 Development of MB 07811 is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top